Our Take
Lilly is betting that GLP drugs work in indications beyond obesity, but the company is licensing rather than building the pipeline itself.
Why it matters
GLP-1 and GLP-2 drugs are now the highest-margin product category in pharma, and Lilly's dominance rests on Mounjaro and tirzepatide. A credible GLP-2 play in GI disease could anchor the next revenue phase as weight-loss market competition intensifies.
Do this week
Investors: cross-reference Hanmi's GLP-2 candidate stage and trial timeline against competitors (Viking Therapeutics, Structure Therapeutics) before the next Lilly earnings call.
Lilly licenses GLP-2 from Hanmi to enter gastrointestinal disease
Eli Lilly announced a licensing deal with South Korean firm Hanmi Pharmaceutical for a GLP-2 candidate. The agreement expands Lilly's GLP franchise beyond weight-loss indications into gastrointestinal disease treatment. No financial terms were disclosed in the announcement.
GLP-2 agonists work on a different receptor than GLP-1 drugs like Mounjaro and Zepbound, which Lilly markets for weight loss and diabetes. GLP-2 candidates are being developed by multiple companies, including Viking Therapeutics and Structure Therapeutics, primarily for short bowel syndrome and other GI conditions.
GLP drugs are now the fastest-growing pharma category; ownership of multiple indications matters
Lilly's GLP-1 franchise generated $5.2 billion in revenue in 2023, a fraction of its current run rate (company-reported). The weight-loss market is crowded: Novo Nordisk leads with Ozempic and Wegovy, while Amgen's MariTide and other entrants are launching. Lilly's Mounjaro holds significant share, but margin compression is inevitable as supply normalizes and competition increases.
A credible GLP-2 entry into GI disease creates a second revenue pillar within the GLP class. It also signals confidence that Lilly's manufacturing and clinical infrastructure can sustain multiple receptor targets in this drug family. Whether Hanmi's candidate has advantage over competitors will depend on trial readouts and timeline.
Hanmi's trial stage and competitive timeline are the real metrics
The licensing announcement omits clinical stage, trial endpoints, and launch timeline for Hanmi's GLP-2 candidate. Lilly's ability to move this asset forward depends on Hanmi's trial data quality and speed. Investors should map Hanmi's program against Viking Therapeutics' VK2735 (phase 2b, multimodal GLP-1/GIP/GCG) and Structure Therapeutics' GSBR-1290 (phase 2a, oral GLP-2) to assess whether Lilly is acquiring a leader or a follower in the GI space.